Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Author Interviews
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Journal of Human Immunity
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research

User menu

  • My alerts

Search

  • Advanced search
Life Science Alliance
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Journal of Human Immunity
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research
  • My alerts
Life Science Alliance

Advanced Search

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Author Interviews
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Follow LSA on Bluesky
  • Follow lsa Template on Twitter

Cancer

  • Synergistic effect of antagonists to KRas4B/PDE6 molecular complex in pancreatic cancer
    Open Access
    Synergistic effect of antagonists to KRas4B/PDE6 molecular complex in pancreatic cancer

    Paola Briseño-Díaz, Michael Schnoor, Martiniano Bello-Ramirez, Jose Correa-Basurto, Arturo Rojo-Domínguez, Leticia Arregui, Libia Vega, Enrique Núñez-González, Luis Andres Palau-Hernández, Carlos Guadalupe Parra-Torres, Óscar Manuel García Córdova, Ernesto Zepeda-Castilla, Eduardo Torices-Escalante, Leticia Domínguez-Camacho, Beatriz Xoconostle-Cazares, Marco Antonio Meraz-Ríos, Sandra Delfín-Azuara, Dayan Andrea Carrión-Estrada, Nicolas Villegas-Sepúlveda, Rosaura Hernández-Rivas, Maria del Rocio Thompson-Bonilla, Miguel Vargas

    Paola Briseño-Díaz ... Miguel Vargas

    Published 9 October 2023

    C14 and P8 combo reveals potent synergy in PDAC models, promising safer, effective therapy than gemcitabine.

  • MUC13 drives cancer aggressiveness and metastasis through the YAP1-dependent pathway
    Open Access
    MUC13 drives cancer aggressiveness and metastasis through the YAP1-dependent pathway

    Kyle Doxtater, Manish K Tripathi, Radhika Sekhri, Bilal B Hafeez, Sheema Khan, Nadeem Zafar, Stephen W Behrman, Murali M Yallapu, Meena Jaggi, Subhash C Chauhan

    Kyle Doxtater ... Subhash C Chauhan

    Published 4 October 2023

    This study reveals that MUC13 plays a critical role in the metastasis-associated processes via interaction with YAP1 and nuclear translocation of the YAP1-mediated survival complex and a biochemical intervention that interferes with MUC13–YAP1 complex formation can help develop new therapeutics.

  • KCNQ potassium channels modulate Wnt activity in gastro-oesophageal adenocarcinomas
    Open Access
    KCNQ potassium channels modulate Wnt activity in gastro-oesophageal adenocarcinomas

    David Shorthouse, Lizhe Zhuang, Eric P Rahrmann, Cassandra Kosmidou, Katherine Wickham Rahrmann, Michael Hall, Benedict M Greenwood, Ginny Devonshire, Richard J Gilbertson, Rebecca C Fitzgerald, Benjamin A Hall

    David Shorthouse ... Benjamin A Hall

    Published 25 September 2023

    KCNQ3, a potassium channel, is frequently genetically altered in gastro-oesophageal adenocarcinomas and found to be significantly associated with WNT and MYC activity, and cellular proliferation.

  • Glioblastoma cellular MAP4K1 facilitates tumor growth and disrupts T effector cell infiltration
    Open Access
    Glioblastoma cellular MAP4K1 facilitates tumor growth and disrupts T effector cell infiltration

    Jin-Min Sun, Hong-Ye Fan, Yan Zhu, Ting-Ting Pan, Yong-Ping Wu, Dao-Yong Zhang, Xiao-Yu Hou

    Jin-Min Sun ... Xiao-Yu Hou

    Published 21 September 2023

    MAP4K1 acts as a cancer cell-intrinsic driver of tumorigenesis and immune evasion in human gliomas, specifically glioblastoma multiforme, by modulating cytokine–chemokine signaling networks.

  • RB loss sensitizes cells to replication-associated DNA damage after PARP inhibition by trapping
    Open Access
    RB loss sensitizes cells to replication-associated DNA damage after PARP inhibition by trapping

    Luis Gregory Zamalloa, Margaret M Pruitt, Nicole M Hermance, Himabindu Gali, Rachel L Flynn, Amity L Manning

    Luis Gregory Zamalloa ... Amity L Manning

    Published 13 September 2023

    After PARP inhibition by trapping, cells lacking the RB tumor suppressor experience persistent replication stress and genomic instability that compromise cell viability.

  • Comprehensive analysis of the lysine succinylome in fish oil-treated prostate cancer cells
    Open Access
    Comprehensive analysis of the lysine succinylome in fish oil-treated prostate cancer cells

    Yifan Jiang, Chao He, Haokai Ye, Qianhan Xu, Xiuyuan Chen, Ying Chen, Jianying Sun, Sonia Rocha, Mu Wang

    Yifan Jiang ... Mu Wang

    Published 8 September 2023

    Through a global lysine succinylation analysis of prostate cancer cells treated with fish oil, a significant number of lysine succinylation sites have been identified and FO-dependent GOT2 succinylation status may have a potential to inhibit building block generation.

  • A new ferrocene derivative blocks K-Ras localization and function by oxidative modification at His95
    Open Access
    A new ferrocene derivative blocks K-Ras localization and function by oxidative modification at His95

    Kristen M Rehl, Jayaraman Selvakumar, Rhonda L Pitsch, Don Hoang, Kuppuswamy Arumugam, Sean W Harshman, Alemayehu A Gorfe, Kwang-Jin Cho

    Kristen M Rehl ... Kwang-Jin Cho

    Published 4 September 2023

    We report redox system regulates KRAS localization and activity via oxidation at His95 residue, and proposes a role of oncogenic K-Ras in the antioxidant-induced growth and metastasis of KRAS-driven cancers.

  • LEF1 enhances β-catenin transactivation through IDR-dependent liquid–liquid phase separation
    Open Access
    LEF1 enhances β-catenin transactivation through IDR-dependent liquid–liquid phase separation

    Bing Zhao, Zhuoxin Li, Shaoqing Yu, Tingting Li, Wen Wang, Ran Liu, Biyu Zhang, Xiya Fang, Yezhuang Shen, Qiuying Han, Xin Xu, Kai Wang, Weili Gong, Tao Li, Ailing Li, Tao Zhou, Weihua Li, Teng Li

    Bing Zhao ... Teng Li

    Published 1 September 2023

    This research elucidates the correlation between liquid–liquid phase separation (LLPS) of LEF1 with β-catenin and their transcriptional activation function, offering a novel therapeutic approach for the treatment of colorectal cancer through LLPS.

  • Decoding the obesity–cancer connection: lessons from preclinical models of pancreatic adenocarcinoma
    Open Access
    Decoding the obesity–cancer connection: lessons from preclinical models of pancreatic adenocarcinoma

    Christian F Ruiz, Cathy Garcia, Jeremy B Jacox, Lauren Lawres, Mandar D Muzumdar

    Christian F Ruiz ... Mandar D Muzumdar

    Published 30 August 2023

    Preclinical models demonstrate that obesity reprograms the pretumor or tumor cell and its micro- and macro-environments to drive cancer development via altered cellular metabolism, hormone dysregulation, inflammation, and microbial dysbiosis.

  • Polo-like kinase-1 mediates hepatitis C virus-induced cell migration, a drug target for liver cancer
    Open Access
    Polo-like kinase-1 mediates hepatitis C virus-induced cell migration, a drug target for liver cancer

    Korri E El-Khobar, Enoch Tay, Eve Diefenbach, Brian S Gloss, Jacob George, Mark W Douglas

    Korri E El-Khobar ... Mark W Douglas

    Published 30 August 2023

    This study identifies PLK1 as a novel protein that promotes liver cancer in people with hepatitis C. The findings suggest a novel drug target for patients with liver cancer to reduce cancer spread and improve survival.

Pages

  • Previous
  • Next
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 24
  • Aging (33)
  • Biophysics (54)
  • Cancer (235)
  • Cell Biology (585)
  • Chemical Biology (23)
  • Chromatin & Epigenetics (133)
  • Development (123)
  • Ecology (5)
  • Evolution (36)
  • Genetics, Gene Therapy & Genetic Disease (131)
  • Genomics & Functional Genomics (167)
  • Immunology (217)
  • Medical Research (98)
  • Metabolism (104)
  • Methods & Resources (89)
  • Microbiology, Virology & Host Pathogen Interaction (157)
  • Molecular Biology (329)
  • Molecular Diagnostics & Diagnostic Imaging (12)
  • Neuroscience (155)
  • Pharmacology & Biotechnology (17)
  • Physiology (45)
  • Plant Science (26)
  • Stem Cells (71)
  • Structural Biology (85)
  • Synthetic Biology (6)
  • Systems & Computational Biology (125)
Advertisement

EMBO Press LogoRockefeller University Press LogoCold Spring Harbor Logo

Content

  • Home
  • Newest Articles
  • Current Issue
  • Archive
  • Subject Collections

For Authors

  • Submit a Manuscript
  • Author Guidelines
  • License, copyright, Fee

Other Services

  • Alerts
  • Bluesky
  • X/Twitter
  • RSS Feeds

More Information

  • Editors & Staff
  • Reviewer Guidelines
  • Feedback
  • Licensing and Reuse
  • Privacy Policy

ISSN: 2575-1077
© 2025 Life Science Alliance LLC

Life Science Alliance is registered as a trademark in the U.S. Patent and Trade Mark Office and in the European Union Intellectual Property Office.